Aripiprazole augmentation for treatment-resistant bipolar depression: Sustained remission after 36 months [3]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 3, 2007, Pages 304-305

  Kemp, David E ^a   Dago, Pedro L ^b   Straus, Joshua L ^b   Fleck, Jenelle ^b   Karaffa, Melissa ^b   Gilmer, William S ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOMIPRAMINE; ESCITALOPRAM; GABAPENTIN; LITHIUM; MIRTAZAPINE; OXCARBAZEPINE; PAROXETINE; QUETIAPINE; SERTRALINE; TEMAZEPAM; VALPROATE SEMISODIUM;

ADULT; AKATHISIA; BIPOLAR DEPRESSION; BIPOLAR II DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PIPERAZINES; PROSPECTIVE STUDIES; QUINOLONES; TREATMENT OUTCOME;

EID: 34248592713     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000270092.32286.d1     Document Type: Letter

References (11)

1. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-771.
2. Keck PE, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebocontrolled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67:626-637.
3. Keck PE, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651-1658.
4. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2004;16:189-194.
5. Hellerstein DJ. Aripiprazole as an adjunctive treatment for refractory major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:1347-1348.
6. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry. 2005;66:1216-1220.
7. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
8. Guy W. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976. Publication no. ADM 76-336.
9. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530-537.
10. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261-269.
11. Abilify [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd; 2005.